← Human Trials & Peer-Reviewed Studies
Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial
Plain-language guide to PMID 29733445 (2018): double-blind randomized controlled trial study of Parathyroid Hormone (PTH 1-84) in 81 women.
Key Facts
- PMID
- 29733445
- Journal
- Clinical endocrinology
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Bislev LS et al. (7 authors)
- DOI
- 10.1111/cen.13734
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.
Emerging evidence supports a positive, bidirectional and clinical relevant interaction between parathyroid hormone (PTH) and the renin-angiotensin-aldosterone-system (RAAS).
The researchers aimed to investigate whether PTH levels are lowered by short-term treatment with an angiotensin 2 receptor blocker (valsartan) independently of coadministration of vitamin D3.
Secondary end-points included effects on blood pressure, cardiac conduction and concentrations of renin and aldosterone.
Who Took Part
According to the abstract, 81 women were involved.
The age groups tagged for this paper are middle-aged adults and older adults, women only.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.
As a double-blind Parathyroid Hormone (PTH 1-84) study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Parathyroid Hormone (PTH 1-84) group a baseline to be compared against.
What Was Measured
The subject headings attached to it are Aldosterone, Angiotensin Receptor Antagonists, Blood Pressure, Cholecalciferol, Electrocardiography, Parathyroid Hormone and Postmenopause.
Author keywords: adrenal, angiotensin 2 receptor blockade and vitamin D.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 81 women.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2018 (Clinical endocrinology), a journal based in England.
More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.